Eran Segal from Weizmann Institute of Science presented The Human Phenotype Project, a large-scale prospective cohort with over 10,000 participants. The project aims to identify novel molecular markers and develop prediction models for disease onset using deep profiling. The profiling includes medical history, lifestyle, blood tests, and molecular profiling of the transcriptome, genetics, microbiome, metabolome and immune system. Why it matters: Such projects demonstrate the growing focus on personalized medicine in the region, utilizing advanced AI and machine learning techniques for disease prevention and treatment.
Professor Eran Segal presented The Human Phenotype Project, a longitudinal cohort study with over 10,000 participants. The project aims to identify molecular markers and develop prediction models for disease using deep profiling techniques including medical history, lifestyle, blood tests, and microbiome analysis. The study provides insights into drivers of obesity, diabetes, and heart disease, identifying novel markers at the microbiome, metabolite, and immune system level. Why it matters: Such large-scale phenotyping initiatives could inform personalized medicine approaches relevant to the Middle East's specific health challenges.
Eduardo da Veiga Beltrame, bioinformatics lead at ImYoo (a Caltech spinout), presented on scalable methods for single-cell omics data analysis, including kallisto|bustools and scvi-tools. He highlighted their use in ImYoo's decentralized longitudinal study on Inflammatory Bowel Disease (IBD), where patients self-collect capillary blood samples. Beltrame also discussed his research on STEM education programs in Brazil as a visiting scholar at UC Berkeley. Why it matters: This highlights the growing trend of decentralized clinical studies leveraging advanced single-cell technologies for precision medicine, showcasing the potential of remote data collection and analysis in understanding complex diseases.
The Human Phenotype Project (HPP), led by researchers from Mohamed bin Zayed University of Artificial Intelligence (MBZUAI), published findings in Nature Medicine detailing an understanding of the health-disease continuum. The HPP involves deep and longitudinal profiling of approximately 28,000 participants, collecting diverse data including medical history, lifestyle, blood tests, and molecular profiling. The project aims to create AI-based predictive models for disease onset and progression, and digital twins to simulate interventions. Why it matters: This research can transform precision medicine and preventative care in the UAE by creating personalized digital twins that can simulate interventions and predict health trajectories.
The KAUST Smart-Health Initiative (KSHI) held its annual forum, showcasing research collaborations with partners like KFSHRC, KAIMRC, and KACST. Projects presented included biomarker detection devices, cardiovascular disease sensors, 3D data visualization, and genome sequencing for patient data analysis. Dr. Sara F. Althari highlighted KAUST's cultivation of partnerships within the Kingdom's healthcare and biotech ecosystem. Why it matters: The KSHI aims to transform Saudi Arabia's healthcare system towards precision and personalized medicine, aligning with Vision 2030.
Agathe Guilloux, a professor in Data Science at Evry Paris Saclay University, presented on machine learning algorithms for precision medicine at MBZUAI. Her talk covered the main challenges of precision medicine and how AI can address them. She also discussed algorithms developed for decision support tools. Why it matters: This highlights MBZUAI's role as a platform for discussing advanced AI applications in healthcare, even when the research is not directly conducted in the GCC.
Natasa Przulj at the Barcelona Supercomputing Center is developing an AI framework that fuses multi-omic data to improve precision medicine. The framework uses graph-regularized non-negative matrix tri-factorization (NMTF) and network science algorithms for patient stratification, biomarker prediction, and drug repurposing. It is applied to diseases like cancer, Covid-19, and Parkinson's. Why it matters: This research can enable more personalized and effective treatments by leveraging complex biological data to understand disease mechanisms and tailor therapies.
This article discusses the use of artificial intelligence in precision oncology, particularly in understanding individual tumor mechanisms and aiding clinical decision-making. Dr. Xinghua Lu, with extensive experience in medicine and biomedical informatics, will present research on individualized Bayesian causal inference methods for investigating oncogenic mechanisms. These methods aim to provide clinical decision support at the cellular, tumor, and patient levels. Why it matters: AI-driven precision oncology can enable more personalized and effective cancer treatments, improving patient outcomes in the region and globally.